A recent vaccine-based approach with important implications for cancer therapy has been reported in which a liposomal delivery system carries a self-tumoral epitope (HER-2/neu-derived peptide) and CpG oligodeoxynucleotides (CpG ODN) as an adjuvant, which elicits a CD8+ mediated immune response and enhances efficacy [129]. The gene discussed is ERBB2; the disease is cancer.